Gilead Sciences Pty Ltd
Regulatory activities for this sponsor.
Loading...
Sponsor content
99 result(s) found, displaying 11 to 20
-
Australian Public Assessment Report (AusPAR)Sunlenca (Lenacapavir) has been approved to treat adults with multidrug resistant HIV 1 infection for whom it is otherwise not possible to construct a suppressive anti-viral regimen.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for SUNLENCA lenacapavir (as sodium) 300 mg film coated tablet blister pack.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for SUNLENCA lenacapavir (as sodium) 463.5 mg/1.5 mL solution for injection vial.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for Cellular Therapies - T Cells - Axicabtagene ciloleucel, cryopreserved - T - Yescarta - Gilead Sciences Pty Ltd - Injection, intravenous infusion - Bag.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for Cellular Therapies - T Cells - Brexucabtagene autoleucel, cryopreserved - T - Tecartus - Gilead Sciences Pty Ltd - Injection, intravenous infusion - Bag.
-
Prescription medicine registrationActive ingredients: sacituzumab govitecan.
-
Prescription medicine decision summaryTGA decision: Sunlenca (lenacapavir sodium) is approved to treat multidrug resistant HIV-1 infection.
-
Prescription medicine registrationActive ingredients: lenacapavir sodium.
-
-